Lonza Group (OTCMKTS:LZAGY) Rating Lowered to Strong Sell at Zacks Research

Lonza Group (OTCMKTS:LZAGY) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

Lonza Group Stock Performance

Shares of OTCMKTS LZAGY opened at $66.36 on Wednesday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.87 and a current ratio of 1.46. Lonza Group has a 1 year low of $55.57 and a 1 year high of $73.85. The firm’s 50 day moving average price is $68.23 and its 200 day moving average price is $68.67.

Lonza Group Company Profile

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.